UNH UNITEDHEALTH GROUP INC

Price Chart

Executive Summary

Raymond James upgraded UnitedHealth Group (UNH) from Market Perform to Outperform with a $330 price target, joining a cluster of 12 firms that have acted on the stock in recent weeks. The upgrade comes despite a PT that sits 11% below the current $370.48 price, indicating a view that risk/reward is improving even if near-term upside is capped. Consensus is heavily bullish: 24 of 34 analysts rate Buy or Strong Buy (71%), with a mean PT of $387.27 implying 4.5% upside. Raymond James has a 54% accuracy rate on 1,636 calls with an average return of 3.4%, placing it in the middle of the peer pack. EPS revisions are strongly positive — current quarter estimates have risen from $4.57 to $4.85 over 30 days, and full-year 2026 EPS has been revised up 2.8% with zero downgrades. Insider activity shows a single small sell, while congressional trades show five buys from both parties. Institutional flows are overwhelmingly bullish: Norges Bank initiated a $4.37B position, Two Sigma added 690%, and Cullen Capital increased 41%. Short interest stands at 56.6% of volume, a high level that could fuel a squeeze. The Raymond James upgrade is a positive catalyst that aligns with broader bullish sentiment, though the below-market PT tempers aggressive near-term expectations.

Impact Score

Consensus & Targets

Of 34 analysts covering UNH, 6 are Strong Buy, 18 Buy, 8 Hold, 1 Sell, and 1 Strong Sell. That yields 71% bullish (Buy/Strong Buy), 23% neutral, and 6% bearish. The consensus is strongly tilted toward the buy side, with the majority of analysts expecting further upside.

The current price of $370.48 sits well above the Raymond James PT of $330. The consensus mean PT is $387.27 (median $400), implying 4.5% upside. The high target is $444 (Oppenheimer), the low is $287 (Baird). Raymond James' $330 is the second-lowest target among all analysts, more than 14% below the mean. This places the firm as a notable outlier on the conservative side.

Recent Analyst Activity

In the last 30 days, there has been 1 upgrade (Raymond James) and 0 downgrades for UNH. EPS revisions are strongly positive: for the current quarter (0q), estimates have risen 6.2% in 30 days (from $4.57 to $4.85) with 16 upward vs 4 downward revisions. For the full fiscal year 2026, estimates have risen 2.8% (from $17.86 to $18.36) with 24 upward revisions and zero downward. The near-term earnings momentum is clearly to the upside.

Firm Track Record — Raymond James

Raymond James accuracy: 54% on 1636 calls | avg return: 3.4%

Industry benchmark: mean 51% ± 11%. Top tier: ≥61% (mean + 1σ). Based on 15 firms with ≥5 scored calls.

Raymond James has a 54% accuracy rate across 1,636 tracked calls, with an average return of 3.4%. This is slightly below the top-tier firms like JPMorgan (67% on 6 calls) and Piper Sandler (67% on 6 calls), but above the worst performers like Truist (33% on 9 calls). Given its large sample size, Raymond James' calls carry moderate weight. Its upgrade is contrarian relative to its own conservative PT but aligned with the overall bullish consensus direction.

Earnings Estimates

Next earnings: Jul 27, 2026

Cross-Platform Signals

Insider trades show one sell of $284k by Conway Patrick Hugh on April 23 — small and not alarming. Congressional trading shows five buys from both parties since February, totaling roughly $68k-$195k. Institutional activity is very bullish: Norges Bank initiated a massive $4.37B position, Two Sigma added 690% (now $49.7M), and Cullen Capital increased 40.7%. There is also a Norges Bank exit noted, potentially a different entity. Short interest ratio is 56.6% — extremely high, indicating heavy bearish positioning that could reverse sharply on positive news. The analyst upgrade converges with bullish institutional flows and earnings revisions, while short interest divergence suggests potential for a squeeze.

Documents Analyzed

Report based on filing metadata.

US Market Status